Literature DB >> 2802558

beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance.

C C Sanders1.   

Abstract

The in vitro activity of four oral cephalosporins was assessed in dilution tests with 50 isolates of the family Enterobacteriaceae possessing well-characterized mechanisms of resistance to beta-lactam antibiotics. The interaction of the drugs with a broad array of beta-lactamases was also determined in spectrophotometric assays and tests for enzyme induction. Overall, the percentages of strains susceptible to each of the study drugs were 82% for cefixime, 62% for cefuroxime, 58% for cephalexin, and 44% for cefaclor. The poor activity of the older cephalosporins was due to a high degree of susceptibility to hydrolysis by both plasmid-mediated and chromosomally mediated beta-lactamases. For cefaclor, higher MICs were associated with higher levels of plasmid-mediated beta-lactamases in the strains. Resistance to cefuroxime was seen primarily among strains expressing high levels of class I or IV beta-lactamase. Resistance to cefixime was seen only among strains expressing high levels of class I enzymes. Neither cefixime nor cefuroxime was a strong inducer of class I beta-lactamases, although enzyme induction did appear to play a role in cefuroxime resistance in a strain of Serratia marcescens. The consistently greater activity of cefixime over cefuroxime was found not to be due to greater drug permeation into the cell. Rather, it appeared to result from the high affinity of the drug for target enzymes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2802558      PMCID: PMC172646          DOI: 10.1128/AAC.33.8.1313

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

Review 1.  Cefuroxime axetil.

Authors:  A M Emmerson
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

2.  Comparative activities of LY 164846 and other orally administered beta-lactam antibiotics against Haemophilus influenzae.

Authors:  J H Jorgensen; J S Redding; A W Howell
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

3.  In-vitro activity and beta-lactamase stability of LY163892.

Authors:  C Cao; N X Chin; H C Neu
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

4.  Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics.

Authors:  C C Sanders; W E Sanders
Journal:  J Infect Dis       Date:  1986-11       Impact factor: 5.226

5.  Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests.

Authors:  C C Sanders; J P Iaconis; G P Bodey; G Samonis
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

7.  In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.

Authors:  P C Fuchs; R N Jones; A L Barry; C Thornsberry; L W Ayers; T L Gavan; E H Gerlach
Journal:  Diagn Microbiol Infect Dis       Date:  1986-07       Impact factor: 2.803

8.  Studies on beta-lactam antibiotics. IX. Synthesis and biological activity of a new orally active cephalosporin, cefixime (FK027).

Authors:  H Yamanaka; T Chiba; K Kawabata; H Takasugi; T Masugi; T Takaya
Journal:  J Antibiot (Tokyo)       Date:  1985-12       Impact factor: 2.649

9.  Comparative antibacterial activity of an arylglycyl oral cephalosporin, LY164846.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

10.  Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

View more
  6 in total

1.  [Clinical experiences with cefixime in the treatment of bacterial infections of the lower respiratory tract].

Authors:  W Kersten; H Müsken
Journal:  Infection       Date:  1990       Impact factor: 3.553

2.  [Treatment results using cefixime for bacterial respiratory tract infections].

Authors:  L Leonhardt
Journal:  Infection       Date:  1990       Impact factor: 3.553

3.  In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci, Enterobacteriaceae and Pseudomonas aeruginosa, including beta-lactamase producers.

Authors:  B Wiedemann; E Luhmer; M T Zühlsdorf
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

4.  5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy. Cefixime Study Group.

Authors:  D Adam; U Hostalek; K Tröster
Journal:  Infection       Date:  1995       Impact factor: 3.553

5.  Spectrofluorimetric determination of cefixime using terbium-danofloxacin probe.

Authors:  Jamshid L Manzoori; Mohammad Amjadi; Naser Soltani; Abolghasem Jouyban
Journal:  Iran J Basic Med Sci       Date:  2014       Impact factor: 2.699

6.  Conjugation to Enterobactin and Salmochelin S4 Enhances the Antimicrobial Activity and Selectivity of β-Lactam Antibiotics against Nontyphoidal Salmonella.

Authors:  Artur Sargun; Martina Sassone-Corsi; Tengfei Zheng; Manuela Raffatellu; Elizabeth M Nolan
Journal:  ACS Infect Dis       Date:  2021-03-10       Impact factor: 5.084

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.